Technical Analysis for GLPG - Galapagos NV

Grade Last Price % Change Price Change
grade D 202.78 0.65% 1.31
GLPG closed up 0.65 percent on Friday, May 29, 2020, on 1.65 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Down
Historical GLPG trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish 0.65%
Stochastic Buy Signal Bullish 0.65%
Oversold Stochastic Weakness 0.65%
Fell Below 50 DMA Bearish 2.52%
MACD Bearish Centerline Cross Bearish 2.52%
200 DMA Support Bullish 2.52%
Lower Bollinger Band Walk Weakness 2.52%
Multiple of Ten Bearish Other 2.52%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Medicine Medical Specialties Immunology Autoimmune Diseases Monoclonal Antibodies Inflammation Rheumatoid Arthritis Psoriasis Inflammatory Bowel Disease Osteoarthritis Inflammatory Diseases Ulcerative Colitis Arthritis Abdominal Pain Colitis Treatment Of Inflammatory Diseases Sle Treatment Of Inflammation

Is GLPG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 274.03
52 Week Low 112.0
Average Volume 132,751
200-Day Moving Average 195.84
50-Day Moving Average 202.96
20-Day Moving Average 214.91
10-Day Moving Average 209.44
Average True Range 8.82
ADX 13.01
+DI 30.05
-DI 32.29
Chandelier Exit (Long, 3 ATRs ) 206.67
Chandelier Exit (Short, 3 ATRs ) 221.46
Upper Bollinger Band 234.12
Lower Bollinger Band 195.70
Percent B (%b) 0.18
BandWidth 17.88
MACD Line -1.96
MACD Signal Line 0.93
MACD Histogram -2.896
Fundamentals Value
Market Cap 10.31 Billion
Num Shares 50.8 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -289.69
Price-to-Sales 23.11
Price-to-Book 3.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 212.59
Resistance 3 (R3) 213.23 210.61 210.96
Resistance 2 (R2) 210.61 208.11 210.29 210.41
Resistance 1 (R1) 206.69 206.56 205.38 206.05 209.86
Pivot Point 204.07 204.07 203.41 203.75 204.07
Support 1 (S1) 200.15 201.57 198.84 199.51 195.70
Support 2 (S2) 197.53 200.02 197.21 195.15
Support 3 (S3) 193.61 197.53 194.61
Support 4 (S4) 192.97